Polyethylene Glycol 3350 in the Treatment of Chronic Idiopathic Constipation: Post hoc Analysis Using FDA Endpoints
Open Access
- 9 September 2022
- journal article
- research article
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2022, 1-8
Abstract
Background & Aims. The efficacy and safety of polyethylene glycol 3350 for chronic idiopathic constipation have been demonstrated in randomized controlled trials. A new US Food and Drug Administration-recommended primary efficacy endpoint for evaluating chronic idiopathic constipation prompted our reevaluation of previously reported clinical data with polyethylene glycol 3350. Methods. This multicenter, double-blind, placebo-controlled, parallel-group trial included adults with chronic idiopathic constipation randomized to polyethylene glycol 3350 17 g (n = 204) or placebo (n = 100) once daily for 24 weeks. Post hoc analyses were performed using the US Food and Drug Administration endpoint (≥3 complete spontaneous bowel movements/week and an increase of ≥1 complete spontaneous bowel movement/week from baseline for ≥9/12 weeks, including 3 of the last 4 weeks) along with additional efficacy and safety outcomes. Results. The proportion of patients meeting the new endpoint was significantly higher with polyethylene glycol 3350 vs placebo (42% vs 13%; ). Reductions in the mean number of hard/lumpy stools/week (–2.1 vs –0.9; ) and the weekly mean five-point cramping rating (–0.3 vs –0.1; ) also significantly favored polyethylene glycol 3350. The proportion of subjects with gastrointestinal adverse events decreased markedly after the first week of treatment in the polyethylene glycol 3350 group. Conclusion. Using the current US Food and Drug Administration-recommended responder definition and other secondary outcomes, once-daily polyethylene glycol 3350 demonstrated substantial and sustained efficacy and safety over 24 weeks in patients with chronic idiopathic constipation. Trial Registration. The original trial was registered with https://clinicaltrials.gov Trial: NCT00153153.Keywords
Funding Information
- Braintree Laboratories
This publication has 18 references indexed in Scilit:
- Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled TrialPLOS ONE, 2015
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Prucalopride in Men With Chronic ConstipationAmerican Journal of Gastroenterology, 2015
- A randomized, double‐blind, placebo‐controlled trial to evaluate the efficacy, safety, and tolerability of long‐term treatment with prucaloprideNeurogastroenterology & Motility, 2015
- American Gastroenterological Association Medical Position Statement on ConstipationGastroenterology, 2013
- Prevalence of, and Risk Factors for, Chronic Idiopathic Constipation in the Community: Systematic Review and Meta-analysisAmerican Journal of Gastroenterology, 2011
- Two Randomized Trials of Linaclotide for Chronic ConstipationNew England Journal of Medicine, 2011
- A Comparison of Polyethylene Glycol Laxative and Placebo for Relief of Constipation From Constipating MedicationsSouthern Medical Journal, 2007
- A Randomized, Multicenter Comparison of Polyethylene Glycol Laxative and Tegaserod in Treatment of Patients With Chronic ConstipationAmerican Journal of Gastroenterology, 2007
- A Randomized, Multicenter, Placebo-Controlled Trial of Polyethylene Glycol Laxative for Chronic Treatment of Chronic ConstipationAmerican Journal of Gastroenterology, 2007
- New Polyethylene Glycol Laxative for Treatment of Constipation in AdultsSouthern Medical Journal, 2001